- Home
- TERN vs VKTX Comparison
TERN vs VKTX Comparison
Compare TERN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | VKTX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TERN | VKTX |
|---|---|---|
| Price | $39.59 | $34.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $48.60 | ★ $87.07 |
| AVG Volume (30 Days) | ★ 4.9M | 2.7M |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $18.92 |
| 52 Week High | $48.26 | $47.87 |
Technical Indicators
Market Signals| Indicator | TERN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 40.71 |
| Support Level | $25.67 | $36.49 |
| Resistance Level | $45.17 | $36.38 |
| Average True Range (ATR) | 3.71 | 1.91 |
| MACD | 0.08 | -0.39 |
| Stochastic Oscillator | 63.41 | 3.88 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.